Screener
Xeris Biopharma Holdings, Inc. XERS Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Xeris Biopharma Holdings, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed November 8, 2024. Open the filing →
- Filed
- Nov 8, 2024
- Fiscal quarter
- Q3 FY2024
- Calendar quarter
- Q3 2024
- Accession
- 0001867096-24-000187
FAQ
- What is Xeris Biopharma Holdings, Inc.'s return on equity?
- Xeris Biopharma Holdings, Inc. (XERS) reported return on equity of -209.8% in Q3 2023.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s return on equity?
- Over 2 years (2020 to 2022), Xeris Biopharma Holdings, Inc.'s return on equity has grown at a -40.3% compound annual growth rate (CAGR), from -378.2% to -134.8%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Xeris Biopharma Holdings, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude